z-logo
Premium
Xultophy: combination therapy for the treatment of type 2 diabetes
Author(s) -
Chaplin Steve,
Patel Vinod
Publication year - 2015
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1382
Subject(s) - medicine , type 2 diabetes , incretin , adverse effect , intensive care medicine , diabetes mellitus , combination therapy , endocrinology
Xultophy is the first product to combine a basal insulin and an incretin mimetic for the treatment of type 2 diabetes. Here Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Vinod Patel outlines its place in therapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here